Repurposing CRISPR/Cas9 for in situ functional assays

RNAi combined with next-generation sequencing has proven to be a powerful and cost-effective genetic screening platform in mammalian cells. Still, this technology has its limitations and is incompatible with in situ mutagenesis screens on a genome-wide scale. Using p53 as a proof-of-principle target...

Descripción completa

Detalles Bibliográficos
Autores principales: Malina, Abba, Mills, John R., Cencic, Regina, Yan, Yifei, Fraser, James, Schippers, Laura M., Paquet, Marilène, Dostie, Josée, Pelletier, Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2013
Materias:
Resource/Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861673/
https://www.ncbi.nlm.nih.gov/pubmed/24298059
http://dx.doi.org/10.1101/gad.227132.113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861673/
https://www.ncbi.nlm.nih.gov/pubmed/24298059
http://dx.doi.org/10.1101/gad.227132.113

Ejemplares similares